Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma

To calculate the delivered lung dose using quantitative volumetric analysis in a cohort of
patients with unresectable hepatocellular carcinoma who undergo selective internal radiation
therapy (SIRT) with Yttrium-90 glass microspheres (TheraSphere®)-and compare this analysis to
the lung dose estimated by established criteria. In addition, this study, will summarize the
pre and post-treatment clinical data to describe the URMC Y-90 experience.

Inclusion Criteria:

- Adults ≥ 18 years with no upper limit.-Receiving Y-90 Therasphere liver directed
therapy

- Pathology proven diagnosis of hepatocellular carcinoma, metastatic colon cancer or
other metastatic diseases to be treated with SIRT (Y-90)

- surgical resection not feasible at time of initiation of pre-treatment workup

-> 6 months projected life span

- ECOG 0-2

Exclusion Criteria:

- previous radioembolization of one or more liver lobes or segments without available
treatment planning and procedural documentation ie. at another facility prior to URMC
Y-90 radioembolization.